Inventor · disambiguated record
Koji Tamada
Also filed as: TAMADA KOJI
25 granted patents·24 pending applications·262 citations·filing 1973–2025
95Inventor score
Top patents by PatentIndex Score
49 records- 0195US9233125B2Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancerDAVILA EDUARDO·Filed 2011·Granted Jan 12, 2016·178 cites·21 claims
- 0294US11931381B2Immunocompetent cell and expression vector expressing regulatory factors of immune functionUNIV YAMAGUCHI·Filed 2022·Granted Mar 19, 2024·3 cites·20 claims
- 0393US10316102B2Car expression vector and car-expressing T cellsUNIV YAMAGUCHI·Filed 2015·Granted Jun 11, 2019·12 cites·19 claims
- 0491US11337997B2Immunocompetent cell and expression vector expressing regulatory factors of immune functionUNIV YAMAGUCHI·Filed 2017·Granted May 24, 2022·5 cites·19 claims
- 0591US10906984B2CAR expression vector and CAR-expressing T cellsUNIV YAMAGUCHI·Filed 2019·Granted Feb 2, 2021·5 cites·32 claims
- 0689US10973893B2Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancerUNIV MARYLAND·Filed 2016·Granted Apr 13, 2021·4 cites·18 claims
- 0787US12005103B2Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancerUNIV MARYLAND·Filed 2021·Granted Jun 11, 2024·1 cites·18 claims
- 0886US10781249B2Anti-GPC3 antibodyUNIV YAMAGUCHI·Filed 2019·Granted Sep 22, 2020·2 cites·8 claims
- 0985US8440185B2Compositions and methods for the treatment of immunologic disordersCHEN LIEPING·Filed 2007·Granted May 14, 2013·5 cites·11 claims
- 1083US10842848B2Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion proteinCYTLIMIC INC·Filed 2016·Granted Nov 24, 2020·2 cites·8 claims
- 1182US12129291B2Anti-GPC3 antibodyUNIV YAMAGUCHI·Filed 2023·Granted Oct 29, 2024·0 cites·15 claims
- 1282US2024299517A1Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancerUNIV MARYLAND·Filed 2024·Application pending·0 cites
- 1382US2024307451A1Immunocompetent cell and expression vector expressing regulatory factors of immune function, and chimeric antigen receptorNOILE IMMUNE BIOTECH INC·Filed 2024·Application pending·0 cites
- 1481US2024226157A1Immunocompetent Cell and Expression Vector Expressing Regulatory Factors of Immune FunctionUNIV YAMAGUCHI·Filed 2024·Application pending·0 cites
- 1576US12448413B2HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cellNEC CORP·Filed 2022·Granted Oct 21, 2025·0 cites·6 claims
- 1675US11304997B2HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cellCYTLIMIC INC·Filed 2019·Granted Apr 19, 2022·0 cites·5 claims
- 1772US11759518B2Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion proteinNEC CORP·Filed 2022·Granted Sep 19, 2023·0 cites·8 claims
- 1872US2024139248A1Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19NOILE IMMUNE BIOTECH INC·Filed 2024·Application pending·0 cites
- 1970US2024269174A1Enhancer for t-cells or b-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in t-cells or b-cellsUNIV YAMAGUCHI·Filed 2023·Application pending·0 cites
- 2068US11617765B2Enhancer for T-cells or B-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in T-cells or B-cellsUNIV YAMAGUCHI·Filed 2018·Granted Apr 4, 2023·0 cites·18 claims
- 2168US10875900B2Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cellsCYTLIMIC INC·Filed 2020·Granted Dec 29, 2020·0 cites·8 claims
- 2267US10590179B2Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cellsCYTLIMIC INC·Filed 2018·Granted Mar 17, 2020·0 cites·2 claims
- 2366US11491204B2Composition comprising poly I:C and LAG-3-IGG fusion proteinCYTLIMIC INC·Filed 2020·Granted Nov 8, 2022·0 cites·5 claims
- 2465US2025268942A1Isolated immune cell expressing a receptor, interleukin-7, and chemokine (c-c motif) ligand 19NOILE IMMUNE BIOTECH INC·Filed 2025·Application pending·0 cites
- 2565US2021253726A1Car expression vector and car-expressing t cellsUNIV YAMAGUCHI·Filed 2020·Application pending·0 cites
- 2664US11618770B2MUC1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using sameNEC CORP·Filed 2020·Granted Apr 4, 2023·0 cites·4 claims
- 2764US4582498AToy with floating ornament enclosed in transparent vesselTAMADA GIKEN KK·Filed 1984·Granted Apr 15, 1986·33 cites·2 claims
- 2863US11718663B2Anti-GPC3 antibodyUNIV YAMAGUCHI·Filed 2018·Granted Aug 8, 2023·0 cites·18 claims
- 2961US11291718B2Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion proteinCYTLIMIC INC·Filed 2017·Granted Apr 5, 2022·0 cites·5 claims
- 3061US2025332195A1Chimeric antigen receptor, cell expressing said receptor, pharmaceutical composition including said cell, method for producing said cell, and polynucleotide or vector including nucleotide sequence encoding said chimeric antigen receptorNOILE IMMUNE BIOTECH INC·Filed 2022·Application pending·0 cites
- 3161US2025121002A1ANTI-EGFRviii ANTIBODY, POLYPEPTIDE, CELL CAPABLE OF EXPRESSING SAID POLYPEPTIDE, PHARMACEUTICAL COMPOSITION COMPRISING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR COMPRISING NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDENOILE IMMUNE BIOTECH INC·Filed 2022·Application pending·0 cites
- 3259US10526388B2Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cellsCYTLIMIC INC·Filed 2016·Granted Jan 7, 2020·0 cites·9 claims
- 3358US3935702AInvertible timerTAMADA KOJI·Filed 1973·Granted Feb 3, 1976·12 cites·3 claims
- 3458US2024400718A1ANTIBODY BINDING TO LINKER OF scFv OR LIKENOILE IMMUNE BIOTECH INC·Filed 2022·Application pending·0 cites
- 3558US2020323920A1Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, il-7 and ccl19NOILE IMMUNE BIOTECH INC·Filed 2018·Application pending·0 cites
- 3656US2021122831A1Chimeric antigen receptorNOILE IMMUNE BIOTECH INC·Filed 2018·Application pending·0 cites
- 3755US2023322898A1Pharmaceutical composition comprising cell expressing chimeric receptorCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3853US10537626B2HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cellCYTLIMIC INC·Filed 2015·Granted Jan 21, 2020·0 cites·2 claims
- 3953US2009214519A1Compositions and Methods for Treating InflammationUNIV JOHNS HOPKINS·Filed 2006·Application pending·0 cites
- 4052US2010203047A1Novel Compositions And Methods For Stimulating Erythropoiesis In A MammalUNIV MARYLAND·Filed 2008·Application pending·0 cites
- 4152US2018057531A1Muc1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using sameNEC CORP·Filed 2016·Application pending·0 cites
- 4252US2022324975A1Antibody cleavage site binding moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 4351US2022401540A1Pharmaceutical compositionCYTLIMIC INC·Filed 2020·Application pending·0 cites
- 4451US2022143094A1Chimeric receptor that recognizes engineered site in antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 4550US2023071098A1Anti-gpc3 single-chain antibody-containing carNOILE IMMUNE BIOTECH INC·Filed 2019·Application pending·0 cites
- 4650US2022401480A1Drug for Treating Cancer, Combination Drug, Drug Composition, Immune Responsive Cell, Nucleic Acid Delivery Vehicle, and ProductNOILE IMMUNE BIOTECH INC·Filed 2020·Application pending·0 cites
- 4749US2013011835A1Compositions and methods for treating inflammationUNIV JOHNS HOPKINS·Filed 2012·Application pending·0 cites
- 4837US2011268741A1Immunotherapy for Contact Dermatitis Using Co-Signal RegulationUNIV JOHNS HOPKINS·Filed 2010·Application pending·0 cites
- 4934US2011280877A1Inhibition of B7-H1/CD80 interaction and uses thereofTAMADA KOJI·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Koji Tamada files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →